CN112839647B - Sarm1抑制剂 - Google Patents

Sarm1抑制剂

Info

Publication number
CN112839647B
CN112839647B CN201980052437.0A CN201980052437A CN112839647B CN 112839647 B CN112839647 B CN 112839647B CN 201980052437 A CN201980052437 A CN 201980052437A CN 112839647 B CN112839647 B CN 112839647B
Authority
CN
China
Prior art keywords
compound
sarm1
compounds
disease
axonal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980052437.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN112839647A (zh
Inventor
R·O·休斯
R·德夫拉吉
T·博萨纳
R·A·杰里斯-派克
A·S·布雷利
J·本特利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Disarm Therapeutics Inc
Original Assignee
Disarm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Disarm Therapeutics Inc filed Critical Disarm Therapeutics Inc
Publication of CN112839647A publication Critical patent/CN112839647A/zh
Application granted granted Critical
Publication of CN112839647B publication Critical patent/CN112839647B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/28—Cinnolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980052437.0A 2018-06-07 2019-06-06 Sarm1抑制剂 Active CN112839647B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682033P 2018-06-07 2018-06-07
US62/682,033 2018-06-07
PCT/US2019/035833 WO2019236879A1 (en) 2018-06-07 2019-06-06 Inhibitors of sarm1

Publications (2)

Publication Number Publication Date
CN112839647A CN112839647A (zh) 2021-05-25
CN112839647B true CN112839647B (zh) 2025-09-23

Family

ID=68769462

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980052437.0A Active CN112839647B (zh) 2018-06-07 2019-06-06 Sarm1抑制剂

Country Status (8)

Country Link
US (1) US12338238B2 (cg-RX-API-DMAC7.html)
EP (1) EP3801500B1 (cg-RX-API-DMAC7.html)
JP (2) JP2021527125A (cg-RX-API-DMAC7.html)
CN (1) CN112839647B (cg-RX-API-DMAC7.html)
CA (1) CA3102645A1 (cg-RX-API-DMAC7.html)
ES (1) ES3028093T3 (cg-RX-API-DMAC7.html)
MA (1) MA52813A (cg-RX-API-DMAC7.html)
WO (1) WO2019236879A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7478142B2 (ja) 2018-06-07 2024-05-02 ディスアーム セラピューティクス, インコーポレイテッド Sarm1阻害剤
CA3102645A1 (en) 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
EP3801503A4 (en) 2018-06-07 2021-12-08 Disarm Therapeutics, Inc. INHIBITORS OF SARM1
CA3123215C (en) 2018-12-19 2024-04-02 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
US12624025B2 (en) 2019-06-06 2026-05-12 Disarm Therapeutics, Inc. Inhibitors of SARM1
JP7319395B2 (ja) 2019-06-14 2023-08-01 ディスアーム セラピューティクス, インコーポレイテッド Sarm1の阻害剤
WO2021050913A1 (en) 2019-09-12 2021-03-18 Disarm Therapeutics, Inc. Inhibitors of sarm1
WO2021108602A1 (en) * 2019-11-26 2021-06-03 Disarm Therapeutics, Inc. Methods and compositions for neuroprotection
CA3174321A1 (en) 2020-04-09 2021-10-14 Disarm Therapeutics, Inc. Indazole derivatives as inhibitors of sarm1
WO2021207308A1 (en) * 2020-04-09 2021-10-14 Disarm Therapeutics, Inc. Condensed pyrazole derivatives as inhibitors of sarm1
EP4158008A4 (en) * 2020-05-27 2024-10-23 Emendobio Inc. BIALELIC KNOCKOUT OF SARM1
TW202334117A (zh) 2020-08-24 2023-09-01 美商達薩瑪治療公司 Sarm1之抑制劑
US20250361234A1 (en) * 2022-06-06 2025-11-27 Nico Therapeutics, Inc. Compounds, compositions, and methods
AU2023294765A1 (en) * 2022-06-17 2024-12-12 Sundance Biosciences, Inc. Kinase modulators and methods of use thereof
JP2026503618A (ja) 2023-01-24 2026-01-29 ディスアーム セラピューティクス, インコーポレイテッド Sarm1阻害剤としての置換された1h-ピラゾール-4-カルボキサミド
CN121399112A (zh) * 2023-04-27 2026-01-23 维泰瑞隆有限公司 Sarm1调节剂、其制备和用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007000240A1 (en) * 2005-06-28 2007-01-04 Sanofi-Aventis Isoquinoline derivatives as inhibitors of rho-kinase
WO2007012422A1 (en) * 2005-07-26 2007-02-01 Sanofi-Aventis Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors
WO2009155121A2 (en) * 2008-05-30 2009-12-23 Amgen Inc. Inhibitors of pi3 kinase
WO2010091310A1 (en) * 2009-02-06 2010-08-12 Elan Pharmaceuticals, Inc. Inhibitors of jun n-terminal kinase
WO2013005157A1 (en) * 2011-07-05 2013-01-10 Lupin Limited Sulfone derivatives and their use as pkm2 modulators for the treatment of cancer
WO2016036636A1 (en) * 2014-09-05 2016-03-10 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
WO2018167800A1 (en) * 2017-03-13 2018-09-20 Impetis Biosciences Limited Fused bicyclic compounds, compositions and applications thereof

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1022214A (en) 1963-01-31 1966-03-09 Sterling Drug Inc Novel 1,3-disubstituted-1,4-dihydro-4-oxo-1,7-naphthyridines and their preparation
US3429887A (en) 1965-01-26 1969-02-25 Sterling Drug Inc 1,7-naphthyridine-3-carboxylic acid derivatives and their preparation
US3506668A (en) 1965-01-26 1970-04-14 Sterling Drug Inc Method of preparing 8-hydroxy-quinolines
US3429882A (en) 1968-03-25 1969-02-25 Geigy Chem Corp 1,2,8,9-tetraazaphenalenes
US3539567A (en) 1968-04-23 1970-11-10 Geigy Chem Corp 8-carboxy-1(2h) phthalazinones
US3624108A (en) 1968-04-23 1971-11-30 Geigy Chem Corp 7-carboxyphthalides
US3761493A (en) 1968-04-23 1973-09-25 Ciba Geigy Corp 3-dibromomethylphthalic anhydride
US3629251A (en) 1968-08-12 1971-12-21 Geigy Chem Corp Derivatives of 9-aminoalkyl-1 2 8 9-tetraazaphenalenes
US3517014A (en) 1969-06-16 1970-06-23 Sterling Drug Inc Method of preparing 8-hydroxyquinoline-3-carboxylic acids
US3711473A (en) 1970-04-06 1973-01-16 Ciba Geigy Corp 3-hydrazino-1,2,8,9-tetraazaphenalenes
DE2449252A1 (de) 1973-10-16 1975-04-17 Fuji Photo Film Co Ltd Waermeentwickelbares, lichtempfindliches material
US4207112A (en) 1974-01-29 1980-06-10 Fuji Photo Film Co., Ltd. Heat developable light-sensitive materials
JPS50123331A (cg-RX-API-DMAC7.html) 1974-03-14 1975-09-27
GB9310700D0 (en) * 1993-05-24 1993-07-07 Zeneca Ltd Novel composition
JP2004509064A (ja) * 2000-04-27 2004-03-25 アボット・ラボラトリーズ 置換フェニルファルネシルトランスフェラーゼ阻害剤
CA2443918C (en) * 2001-04-11 2012-06-05 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents containing rho kinase inhibitors
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
WO2005102345A1 (en) * 2004-03-30 2005-11-03 Alcon, Inc. Use of rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
US20060078890A1 (en) * 2004-10-08 2006-04-13 Ole Isacson Methods for identifying parkinson's disease therapeutics
US7915410B2 (en) 2005-09-09 2011-03-29 Bristol-Myers Squibb Company Acyclic IKur inhibitors
GB0605766D0 (en) 2006-03-22 2006-05-03 Ucb Sa Process
WO2008001369A1 (en) * 2006-06-27 2008-01-03 Pharmos Corporation Use of cb2 receptor agonists for promoting neurogenesis
AU2007272533A1 (en) * 2006-07-13 2008-01-17 Novartis Ag Use of trifluoromethyl substituted benzamides in the treatment of neurological disorders
JP2010053073A (ja) 2008-08-28 2010-03-11 Sankyo Kasei Kk ハロゲン化イソキノリン類の製造方法
DE102011009961A1 (de) * 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate
USRE47009E1 (en) * 2011-02-01 2018-08-28 The Children's Hospital Of Philadelphia HDAC inhibitors and therapeutic methods using the same
WO2012178022A2 (en) 2011-06-24 2012-12-27 University Of Massachusetts Therapeutic applications targeting sarm1
DE102012019369A1 (de) * 2012-10-02 2014-04-03 Merck Patent Gmbh 7-Azaindolderivat
DK3013804T3 (en) 2013-06-24 2017-04-10 Merck Patent Gmbh phthalazine
WO2015050471A1 (en) 2013-10-02 2015-04-09 Obschestvo S Ogranichennoy Otvetstvennost'yu "Panacela Labs" Carbazole compounds and methods of using same
WO2015102929A1 (en) 2013-12-30 2015-07-09 Novartis Ag Tricyclic sulfonamide derivatives
FR3017868A1 (fr) * 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP6581111B2 (ja) * 2014-04-28 2019-09-25 メッドシャイン ディスカバリー インコーポレイテッド Rhoキナーゼ阻害剤としてのイソキノリンスルホン誘導体
US10729680B2 (en) 2016-01-14 2020-08-04 Bayer Pharma Aktiengesellschaft 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines
EP4091622A1 (en) 2016-08-16 2022-11-23 Henry Ford Health System Compositions for the treatment of chemotherapy-induced neuropathic pain
EP3515426A1 (en) 2016-09-24 2019-07-31 Washington University INHIBITORS OF SARM1 NADase ACTIVITY AND USES THEREOF
CA3102645A1 (en) 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
JP7478142B2 (ja) 2018-06-07 2024-05-02 ディスアーム セラピューティクス, インコーポレイテッド Sarm1阻害剤
EP3801503A4 (en) 2018-06-07 2021-12-08 Disarm Therapeutics, Inc. INHIBITORS OF SARM1
CN109180642A (zh) 2018-10-04 2019-01-11 南京先进生物材料与过程装备研究院有限公司 酞嗪酮类btk抑制剂及其应用
CN109485636A (zh) 2018-10-04 2019-03-19 南京先进生物材料与过程装备研究院有限公司 一种新型btk激酶抑制剂的盐酸盐及其制备方法与用途
CN109223787A (zh) 2018-10-04 2019-01-18 南京先进生物材料与过程装备研究院有限公司 一种喜树碱和新型酞嗪酮类化合物联合用药物组合物
CN109293635A (zh) 2018-10-04 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种新型btk激酶抑制剂的p晶型及其制备方法
CN109336863A (zh) 2018-10-04 2019-02-15 南京先进生物材料与过程装备研究院有限公司 一种新型酞嗪酮类btk抑制剂、制备及其应用
CN112955150A (zh) 2018-10-19 2021-06-11 达萨玛治疗公司 与nad+或nad+前体组合的sarm1抑制剂
CN109481441A (zh) 2018-10-31 2019-03-19 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和新型甲氧基酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109394766A (zh) 2018-10-31 2019-03-01 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和对苯硝基酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109276571A (zh) 2018-10-31 2019-01-29 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和新型硝基酞嗪酮btk抑制剂联合用药物组合物及其应用
CN109331018A (zh) 2018-10-31 2019-02-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和硝基酞嗪酮btk抑制剂联合用药物组合物及其应用
CN109172562A (zh) 2018-10-31 2019-01-11 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和甲氧基酞嗪酮类btk抑制剂联合用药物组合物及其应用
JP7506746B2 (ja) 2020-06-25 2024-06-26 富士フイルム株式会社 腸管上皮細胞の製造方法、及びその利用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007000240A1 (en) * 2005-06-28 2007-01-04 Sanofi-Aventis Isoquinoline derivatives as inhibitors of rho-kinase
WO2007012422A1 (en) * 2005-07-26 2007-02-01 Sanofi-Aventis Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors
WO2009155121A2 (en) * 2008-05-30 2009-12-23 Amgen Inc. Inhibitors of pi3 kinase
WO2010091310A1 (en) * 2009-02-06 2010-08-12 Elan Pharmaceuticals, Inc. Inhibitors of jun n-terminal kinase
WO2013005157A1 (en) * 2011-07-05 2013-01-10 Lupin Limited Sulfone derivatives and their use as pkm2 modulators for the treatment of cancer
WO2016036636A1 (en) * 2014-09-05 2016-03-10 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
WO2018167800A1 (en) * 2017-03-13 2018-09-20 Impetis Biosciences Limited Fused bicyclic compounds, compositions and applications thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Domino Inverse Electron-Demand Diels-Alder/Cyclopropanation Reaction of Diazines Catalyzed by a Bidentate Lewis Acid;KESSLER SIMON等;JOURNAL OF THE AMERICAN CHEMICAL SOCIETY;第134卷(第43期);17885-17888 *
Kitaoka Yasushi等.Axonal protection by ripasudil,a rho kinase inhibitor, via modulating autophagy in TNF-Induced Optic Nerve Degeneration.Investigative Opthalmology & Visual Science.2017,第58卷(第12期),5056. *
phthalazine derivatives from aromatic aldazines;Robev Stefan K等;TETRAHEDRON LETTERS;第22卷(第4期);345-348 *
PREPARATION AND CYCLIzATION OF 2-HYDRAZINO-1- PENTAFLUOROPHENYLETHANOL;PETROV V P等;CHEMISTRY OF HETEROCYCLIC COMPOUNDS;第6卷(第3期);381-364 *
Synthesis and SAR exploration of dinapsoline analogues;S SIT等;BIOORGANIC & MEDICINAL CHEMISTRY;第12卷(第4期);715-734 *
The Novel Rho Kinese(ROCK) Inhibitor K-115: A new candidate drug for neuroprotective treatment in glaucoma;Kotaro Yamamoto等;Investigative Opthalmology & Visual Science;第55卷(第11期);7126-7136 *

Also Published As

Publication number Publication date
US20210261540A1 (en) 2021-08-26
ES3028093T3 (en) 2025-06-18
JP7576145B2 (ja) 2024-10-30
US12338238B2 (en) 2025-06-24
JP2024037770A (ja) 2024-03-19
WO2019236879A1 (en) 2019-12-12
CN112839647A (zh) 2021-05-25
EP3801500A4 (en) 2022-03-02
EP3801500B1 (en) 2025-03-05
JP2021527125A (ja) 2021-10-11
CA3102645A1 (en) 2019-12-12
EP3801500A1 (en) 2021-04-14
MA52813A (fr) 2021-04-14

Similar Documents

Publication Publication Date Title
CN112839648B (zh) Sarm1抑制剂
CN113950326B (zh) Sarm1抑制剂
CN112839647A (zh) Sarm1抑制剂
CN112867489A (zh) Sarm1抑制剂
Kirkland et al. Senolytic drugs: from discovery to translation
CN113164508B (zh) 与神经保护剂组合的sarm1抑制剂
CN115916764B (zh) 作为sarm1抑制剂的吲唑衍生物
CN115175900B (zh) Sarm1的抑制剂
KR102516695B1 (ko) 단백질 내로의 비-천연 아미노산의 혼입
TWI761444B (zh) 己糖激酶2專一性抑制劑在急性中樞神經系統損傷疾病中的應用
JP2024032952A (ja) 異所性石灰化障害を治療するための組成物およびそれを使用する方法
CN114728007B (zh) Sarm1的抑制剂
US20220090086A1 (en) Identification of molecular pathways and methods of use thereof for treating retinal neurodegeneration and other neurodegenerative disorders
WO2012006551A2 (en) Neuroprotective molecules and methods of treating neurological disorders and inducing stress granules
WO2004101787A1 (ja) ハンチンチン遺伝子の発現抑制
CN116568678B (zh) Sarm1的苯并吡唑抑制剂
CN116075511B (zh) 作为sarm1抑制剂的稠合吡唑衍生物
KR20250006359A (ko) Sirna 생체 이용률을 개선하기 위한 galnac 조성물
WO2023202686A1 (zh) 用于抑制黄嘌呤脱氢酶(xdh)的组合物和方法
TW202334414A (zh) 用於抑制黑皮質素2受體和細胞色素p450 11b1表現之組成物及方法
KR20110101391A (ko) Dkk3 발현 또는 활성 억제제를 함유하는 암 예방 및 치료용 조성물
Sun et al. Antihypoxic effect of miR-24 in SH-SY5Y cells under hypoxia via downregulating expression of neurocan
JP5907564B2 (ja) ウィルス性疾患の治療のための組成物及び方法
KR20240139057A (ko) 프리칼리크레인(pkk) 단백질의 발현을 억제하기 위한 조성물 및 방법
JP5697229B2 (ja) 血管新生阻害剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant